Search

Your search keyword '"Kanao, Kent"' showing total 30 results
Start Over Author "Kanao, Kent" Search Limiters Available in Library Collection
30 results on '"Kanao, Kent"'

8. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib

Author

Nishimoto, Koshiro, primary, Shirotake, Suguru, additional, Miyama, Yu, additional, Kaneko, Go, additional, Kanao, Kent, additional, Igarashi, Daisuke, additional, Takahashi, Takayuki, additional, Umezawa, Yuta, additional, Yasuda, Masanori, additional, and Oyama, Masafumi, additional

Published
2022
Full Text
View/download PDF

17. Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma

Author

Mizuno, Ryuichi, Kimura, Go, Fukasawa, Satoshi, Ueda, Takeshi, Kondo, Tsunenori, Hara, Hidehiko, Shoji, Sunao, Kanao, Kent, Nakazawa, Hayakazu, Tanabe, Kazunari, Horie, Shigeo, Oya, Mototsugu, Yuasa, T., Horiguchi, A., Nakaigawa, N., Oyama, M., Nagata, H., Ishida, M., Kawata, N., Hatano, T., Kishida, T., Morita, J., Yamaguchi, R., Nakagawa, T., and Kume, H.

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Indoles, sunitinib, Angiogenesis Inhibitors, Kaplan-Meier Estimate, 0302 clinical medicine, Renal cell carcinoma, Prospective Studies, T helper type 1 lymphocyte, Angiogenic Proteins, Prospective cohort study, Whole blood, Univariate analysis, Sunitinib, General Medicine, Middle Aged, Kidney Neoplasms, Treatment Outcome, 030220 oncology & carcinogenesis, Original Article, Female, Inflammation Mediators, medicine.drug, Adult, medicine.medical_specialty, renal cell carcinoma, interleukin 8, Disease-Free Survival, 03 medical and health sciences, Immune system, Clinical Research, Internal medicine, medicine, Biomarkers, Tumor, Humans, Pyrroles, Interleukin 8, Carcinoma, Renal Cell, Aged, Proportional Hazards Models, Proportional hazards model, business.industry, Original Articles, medicine.disease, 030104 developmental biology, ROC Curve, Immunology, High sensitivity C‐reactive protein, business
Abstract

The objective of this prospective study was to identify baseline angiogenic and inflammatory markers in serum as well as the baseline levels of immune cells in whole blood to predict progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib. Blood samples were collected at baseline in all 90 patients to analyze serum angiogenic and inflammatory markers together with peripheral blood immunological marker. The association between each marker and sunitinib efficacy was analyzed. Univariate and multivariate Cox proportional model analyses were used to assess the correlation between those markers with survival. Baseline levels of interleukin-6, interleukin-8, high sensitivity C-reactive protein and myeloid-derived suppressor cells were significantly higher in patients who progressed when compared with those with clinical benefit. Analysis by the Cox regression model showed that baseline interleukin-8, high sensitivity C-reactive protein and percentage of T helper type 1 cells were significantly associated with progression-free survival in univariate analysis. Furthermore, in multivariate analysis, those three markers were independent indices to predict progression-free survival. In conclusion, angiogenic (interleukin-8), inflammatory (interleukin-6, high sensitivity C-reactive) and immunologic (myeloid-derived suppressor cells, percentage of T helper type 1 cells) markers at baseline would predict the response to sunitinib therapy and/or disease progression in patients with metastatic renal cell carcinoma.

Published
2017

19. A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis‐assisted transurethral resection involving orally administered 5‐aminolevulinic acid

Author

Watanabe, Keitaro, primary, Shirotake, Suguru, additional, Umezawa, Yuta, additional, Takahashi, Takayuki, additional, Yamanaka, Takeshi, additional, Santo, Noriaki, additional, Okabe, Takashi, additional, Kaneko, Gou, additional, Sano, Katsuhiro, additional, Yasuda, Masanori, additional, Kanao, Kent, additional, Oyama, Masafumi, additional, and Nishimoto, Koshiro, additional

Published
2019
Full Text
View/download PDF

22. Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy

Author

Kaneko, Go, primary, Shirotake, Suguru, additional, Nishimoto, Koshiro, additional, Miyazaki, Yasumasa, additional, Ito, Keiichi, additional, Ito, Yujiro, additional, Hagiwara, Masayuki, additional, Kanao, Kent, additional, Nakagawa, Ken, additional, Momma, Tetsuo, additional, Asano, Tomohiko, additional, Tanaka, Nobuyuki, additional, Mizuno, Ryuichi, additional, Oya, Mototsugu, additional, and Oyama, Masafumi, additional

Published
2019
Full Text
View/download PDF

23. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

Author

Ito, Keiichi, primary, Masunaga, Ayako, additional, Tanaka, Nobuyuki, additional, Mizuno, Ryuichi, additional, Shirotake, Suguru, additional, Yasumizu, Yota, additional, Ito, Yujiro, additional, Miyazaki, Yasumasa, additional, Hagiwara, Masayuki, additional, Kanao, Kent, additional, Mikami, Shuji, additional, Momma, Tetsuo, additional, Masuda, Takeshi, additional, Nakagawa, Ken, additional, Oyama, Masafumi, additional, Asano, Tomohiko, additional, and Oya, Mototsugu, additional

Published
2018
Full Text
View/download PDF

24. 膀胱憩室内に発生した神経内分泌癌の1例

Author

Muramatsu, Hiroyuki, Kanao, Kent, Morinaga, Shingo, Kajikawa, Keishi, Kobayashi, Ikuo, Nishikawa, Genya, Yoshizawa, Takahiko, Kato, Yoshiharu, Watanabe, Masahito, Zennami, Kenji, Nakamura, Kogenta, and Sumitomo, Makoto

Subjects
Primary carcinoma in a vesical diverticulum, Neuroendocrine carcinoma, 494.9, urologic and male genital diseases
Abstract

We report a case of neuroendocrine carcinoma in a diverticulum of the bladder. A 65-year-old Japanese woman visited our hospital with the chief complaint of gross hematuria. Cystoscopy revealed a non-papillary broad-based tumor in a diverticulum of the posterior wall. She underwent transurethral resection of bladder tumor (TURBT) and subsequently total cystectomy with ileal conduit on the diagnosis of an invasive urothelial carcinoma. There was no residual tumor in the surgical specimen. Immunohistochemistry of TUR specimens showed positive synaptophysin, chromogranin A, CD56 and high ratio of positive Ki-67. Finally, it was diagnosed as a neuroendocrine carcinoma of the bladder. To our knowledge, this is the second case report of the neuroendocrine tumor or small cell carcinoma in a diverticulum of the urinary bladder in the Japanese literature.

Published
2014

26. Abstract 3961: Increased CCR4-positive regulatory T cells in biopsy specimen of poor prognosis prostate cancer

Author

Watanabe, Masahito, primary, Kanao, Kent, additional, Suzuki, Susumu, additional, Muramatsu, Hiroyuki, additional, Morinaga, Shingo, additional, Kajikawa, Keishi, additional, Kobayashi, Ikuo, additional, Nishikawa, Genya, additional, Kato, Yoshiharu, additional, Nakamura, Kogenta, additional, Yoshikawa, Kazuhiro, additional, Ueda, Ryuzo, additional, and Sumitomo, Makoto, additional

Published
2017
Full Text
View/download PDF

27. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.

Author

Ito, Keiichi, Masunaga, Ayako, Tanaka, Nobuyuki, Mizuno, Ryuichi, Shirotake, Suguru, Yasumizu, Yota, Ito, Yujiro, Miyazaki, Yasumasa, Hagiwara, Masayuki, Kanao, Kent, Mikami, Shuji, Momma, Tetsuo, Masuda, Takeshi, Nakagawa, Ken, Oyama, Masafumi, Asano, Tomohiko, and Oya, Mototsugu

Published
2019
Full Text
View/download PDF

29. New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma.

Author

Saito T, Kanao K, Matsumoto K, Fukumoto K, Igarashi D, Takahashi T, Kaneko G, Shirotake S, Nishimoto K, Mizuno R, Ishida M, Hara S, Oya M, and Oyama M

Abstract

Objectives: We aim to evaluate the risk of recurrence after neoadjuvant chemotherapy followed by radical cystectomy, particularly in ypT2 disease in patients with urothelial carcinoma, because it is not clear if all eligible patients with high-risk muscle-invasive urothelial carcinoma should be treated with adjuvant nivolumab., Materials and Methods: We analysed the radiological and clinicopathological features, including cT and ypT stages, of 197 patients who had undergone two to four cycles of cisplatin-based neoadjuvant chemotherapy and radical cystectomy without adjuvant chemotherapy. We stratified the risk of postoperative recurrence by these factors., Results: The median observation period was 29.6 (interquartile range, 11.4-71.7) months, and disease recurrence was observed in 58 patients. Multivariate analysis revealed that ypT stage ( P  = 0.019) and lymphovascular invasion ( P  = 0.015) were independent risk factors for postoperative recurrence. The ypT2 group ( n  = 38) had significantly better recurrence-free survival than the ypT3 group ( n  = 41) (median recurrence-free survival: not reached vs. 13.4 months, respectively, P  = 0.005). In ypT2 disease, the cT2 and ypT2 group ( n  = 15), which was diagnosed as cT2 preoperatively and then diagnosed as ypT2 postoperatively, had significantly better recurrence-free survival than the cT3/4 and ypT2 group ( n  = 23) (median recurrence-free survival: not reached vs. 63.1 months, respectively, P  = 0.034). There was no significant difference in recurrence-free survival between the ypT ≤ 1 ( n  = 106) and the cT2 and ypT2 groups (median recurrence-free survival: not reached in both, P  = 0.962)., Conclusion: Patients with cT2 and ypT2 stage have a relatively low risk of recurrence and thus have a lower need for adjuvant nivolumab, particularly those with ypT2., Competing Interests: All authors have no conflict of interest to disclose., (© 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.)

Published
2023
Full Text
View/download PDF

30. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.

Author

Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, and Murai M

Subjects
Albumins metabolism, Animals, Antineoplastic Agents pharmacology, Benzamides chemistry, Body Mass Index, Body Weight, Cell Line, Tumor, Cyclohexanones chemistry, Disease Models, Animal, Dose-Response Relationship, Drug, Hematocrit, Humans, Interleukin-6 biosynthesis, Interleukin-6 blood, Interleukin-6 metabolism, Male, Mice, Mice, Inbred BALB C, Muscle, Skeletal drug effects, Neoplasm Transplantation, Time Factors, Triglycerides blood, Weight Loss drug effects, Benzamides pharmacology, Cachexia prevention & control, Cyclohexanones pharmacology, NF-kappa B antagonists & inhibitors, Prostatic Neoplasms complications, Prostatic Neoplasms drug therapy
Abstract

Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor kappaB (NF-kappaB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer., Experimental Design: The association between serum IL-6 levels and variables of cachexia was evaluated in 98 patients with prostate cancer. The inhibitory effects of DHMEQ on IL-6 secretion and cachexia were investigated in in vitro and in vivo studies using JCA-1 cells derived from human prostate cancer., Results: Serum IL-6 levels were significantly elevated and cachexia developed in JCA-1 tumor-bearing mice as well as in prostate cancer patients with progressive disease. IL-6 secretion was significantly inhibited in JCA-1 cells exposed to DHMEQ. Intraperitoneal administration of DHMEQ (8 mg/kg) to tumor-bearing mice produced a significant amelioration of the reduction in body weight, epididymal fat weight, gastrocnemius muscle weight, hematocrit, and serum levels of triglyceride and albumin when compared with administration of DMSO or no treatment. DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P < 0.05)., Conclusions: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-kappaB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion. DHMEQ seems to show promise as a novel and unique anticachectic agent in hormone-refractory prostate cancer.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results